Drug firm Suven Life Sciences has been granted a patent from Europe and two product patents from Eurasia for a drug used in the treatment of neuro-degenerative diseases.
Reportedly, the patents are valid through 2029, 2030 and 2031, respectively. With these clearances, Suven Life Sciences has a total of 21 granted patents from Europe and 19 from Eurasia.
- Will meet high unmet medical needs of cognitive disorders
- Has a huge market potential globally
These granted patents are exclusive intellectual property of Suven Life Sciences and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II.